Product
Control Arm
Aliases
AIN457, Control Arm - placebo
4 clinical trials
8 indications
Indication
PsoriasisIndication
Non-alcoholic Fatty Liver DiseaseIndication
Graft-versus-host diseaseIndication
RelapseIndication
ENPP1 DeficiencyIndication
X-linked HypophosphatemiaIndication
Bladder CancerClinical trial
A Randomized, Double-blind, Multicenter, 24-week Study of Subcutaneous Secukinumab to Assess Anti-interleukin-17A Treatment in Plaque Psoriasis Patients With Coexisting Non-alcoholic Fatty Liver Disease (pINPOINt)Status: Terminated, Estimated PCD: 2021-06-29
Clinical trial
A Phase 2, Open-label Study to Evaluate Graft-vs-host Disease Prophylaxis With High Dose Thymoglobulin, Methotrexate, and Low-dose Cyclosporine in Comparison to Historical/Concurrent Controls Who Received Low Dose Thymoglobulin, Methotrexate, and High-dose CyclosporineStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) DeficiencyStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2024-07-01